The impact of microbial keratitis on quality of life in Uganda. by Arunga, Simon et al.
LSHTM Research Online
Arunga, Simon; Wiafe, Geoffrey; Habtamu, Esmael; Onyango, John; Gichuhi, Stephen; Leck, Astrid;
Macleod, David; Hu, Victor; Burton, Matthew J; (2019) The impact of microbial keratitis on quality of
life in Uganda. BMJ Open Ophthalmology, 4 (1). e000351. DOI: https://doi.org/10.1136/bmjophth-
2019-000351
Downloaded from: http://researchonline.lshtm.ac.uk/id/eprint/4655964/
DOI: https://doi.org/10.1136/bmjophth-2019-000351
Usage Guidelines:
Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively
contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
https://researchonline.lshtm.ac.uk
Arunga S, et al. BMJ Open Ophth 2019;4:e000351. doi:10.1136/bmjophth-2019-000351 1
Original research
The impact of microbial keratitis on 
quality of life in Uganda
Simon Arunga   ,1,2 Geoffrey Wiafe,2 Esmael Habtamu,3,4 John Onyango,2 
Stephen Gichuhi,5,6 Astrid Leck,7 David Macleod,8 Victor Hu,9 Matthew Burton10
To cite: Arunga S, Wiafe G, 
Habtamu E, et al.  The impact 
of microbial keratitis on 
quality of life in Uganda. 
BMJ Open Ophthalmology 
2019;4:e000351. doi:10.1136/
bmjophth-2019-000351
 ► Additional material is 
published online only. To view 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ 
bmjophth- 2019- 000351).
Received 4 June 2019
Revised 4 September 2019
Accepted 1 December 2019
For numbered affiliations see 
end of article.
Correspondence to
Dr Simon Arunga;  Simon. 
Arunga@ lshtm. ac. uk
© Author(s) (or their 
employer(s)) 2019. Re- use 
permitted under CC BY. 
Published by BMJ.
ABSTRACT
Background Microbial keratitis (MK) is a frequent cause 
of sight loss in sub- Saharan Africa. However, no studies have 
formally measured its impact on quality of life (QoL) in this 
context.
Methods As part of a nested case–control design for risk 
factors of MK, we recruited patients presenting with MK 
at two eye units in Southern Uganda between December 
2016 and March 2018 and unaffected individuals, 
individually matched for sex, age and location. QoL was 
measured using WHO Health- Related and Vision- Related 
QoL tools (at presentation and 3 months after start of 
treatment in cases). Mean QoL scores for both groups 
were compared. Factors associated with QoL among the 
cases were analysed in a linear regression model.
Results 215 case- controls pairs were enrolled. The 
presentation QoL scores for the cases ranged from 20 to 65 
points. The lowest QoL was visual symptom domain; mean 
20.7 (95% CI 18.8 to 22.7) and the highest was psychosocial 
domain; mean 65.6 (95% CI 62.5 to 68.8). At 3 months, QoL 
scores for the patients ranged from 80 to 90 points while 
scores for the controls ranged from 90 to 100. The mean 
QoL scores of the cases were lower than controls across all 
domains. Determinants of QoL among the cases at 3 months 
included visual acuity at 3 months and history of eye loss.
Conclusion MK severely reduces QoL in the acute 
phase. With treatment and healing, QoL subsequently 
improves. Despite this improvement, QoL of someone 
affected by MK (even with normal vision) remains lower 
than unaffected controls.
BACkgRound
Microbial keratitis (MK) has been described 
as a ‘silent epidemic’, which leads to substan-
tial morbidity, related to sight loss, pain and 
stigma.1 It is the leading cause of unilateral 
blindness after cataract in tropical regions, 
estimated at 2 million cases of monocular 
blindness per year.2 3 1.3 million individuals 
were bilaterally blind from corneal opacity 
globally (excluding trachoma and vitamin A 
deficiency), accounting for 3.2% of binocular 
blindness.3
Quality of life (QoL) is a very important 
consideration in the management of any 
disease and treatments should ultimately aim 
to maintain or restore QoL.4 Few studies from 
sub- Saharan Africa (SSA) have examined the 
effect of cataract and trachomatous trichiasis 
on QoL.5–7 These have generally examined 
both the general health- related quality of life 
(HRQoL) and more specific vision- related 
quality of life (VRQoL).
However, there is no published data on 
the impact of MK on QoL from SSA, and 
very little from other World regions. In the 
Mycotic Ulcer Treatment Trial 1 (MUTT1) 
in India which compared topical natamycin 
to topical voriconazole for the treatment of 
fungal keratitis, QoL scores at 3 months were 
compared between the two treatment arms. 
However, there was no comparison group of 
unaffected individuals.8 There is a need to 
better understand how MK and its outcomes 
affect people, to develop improved manage-
ment, counselling and support.
To investigate the impact of MK on QoL, 
we conducted this study in South- Western 
Uganda. Here, we describe the QoL among 
patients with MK, at presentation and 3 
Significance of the study
What is already known about this subject?
 ► Quality of life (QoL) is affected in many bilateral 
ocular conditions such as cataract, glaucoma and 
trichiasis.
 ► The impact of microbial keratitis (MK) on QoL com-
pared to unaffected individuals has not been previ-
ously reported.
 ► MK is a common cause of blindness in Sub- Saharan 
Africa.
What are the new findings?
 ► MK severely reduces QoL in the acute phase of the 
disease.
 ► QoL improves with treatment and healing.
 ► Despite improvement, QoL of someone affected by 
MK (even with normal vision) remains lower than 
unaffected controls.
How might these results change the focus of 
research or clinical practice?
 ► The focus of this study is to make the case that MK, 
although usually a uniocular disease severely reduc-
es the QoL of the affected individuals.
 ► QoL is affected in many bilateral ocular conditions 
such as cataract, glaucoma and trichiasis.
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Table 1 Baseline characteristics among the 215 case–
control pairs (matched on gender and village and adjusted 
for age)
Exposure
Cases 
(215)
Controls 
(215)
P valuen (%) n (%)
Married (yes) * 154 (72) 143 (67) 0.215
Head of household (yes) † 146 (68) 140 (65) 0.441
Education status ‡
  None 60 (28) 48 (22) 0.148
  Primary 110 (51) 114 (53)
  Secondary 31 (14) 32 (15)
  Tertiary 14 (7) 21 (10)
Farmer (yes) ‡ 157 (73) 168 (78) 0.144
Size of the household §
  Small (1–4 people) 50 (23) 109 (51) 0.05
  Medium (5–10 people) 115 (54) 94 (44)
  Large (>11 people) 50 (23) 12 (5)
Self- reported wealth 
status ¶
  Poor 36 (17) 20 (9) 0.003
  Middle 158 (73) 188 (88)
  Upper 21 (10) 6 (3)
*People who were married, or cohabiting were considered as 
married while those who were divorced, single or widowed were 
considered as not married.
†Being head of the household meant people who were responsible 
for the overall care of the family, this was regardless of gender: 
among the cases and controls, 31% and 23% were female heads 
of households, respectively.
‡Majority of the participants had no or minimal education (primary 
level) which is not uncommon for a predominantly rural population 
in Uganda. Subsistence farming is the main occupation for this 
population.
§Majority of the household sizes were medium to large (five people 
or more). This is not uncommon since most of the living in rural 
Uganda is largely in an extended family setting.
¶Self- reported wealth status was classified as poor (1, ‘very poor’ 
and 2 ‘poor’), middle (3, ‘neither poor nor rich’) upper (4, ’rich’ and 
5, ‘very rich’). There was one missing value among the control 
group. Participants were asked to compare themselves to their 
neighbours and give a score of their economic status.
months after presentation compared with the QoL of 
unaffected individuals recruited from the community 
who were individually matched for age, sex and location 
of residence.
MeTHodS
ethical statement
This study adhered to the tenets of the Declaration of 
Helsinki. It was approved by the London School of 
Hygiene & Tropical Medicine Ethics Committee (Ref 
10647), Mbarara University Research Ethics Committee 
(Ref 10/04–16) and Uganda National Council for 
Science and Technology (Ref HS-2303). Written, 
informed consent in the local language was obtained 
before enrolment. If the potential participant was unable 
to read, the information was read to them, and they were 
asked to indicate their consent by application of their 
thumbprint, which was independently witnessed.
Study design and participants
This study of the impact of MK on QoL was nested within 
a case- control study of MK in Uganda. We prospectively 
enrolled patients with MK that presented to Ruharo Eye 
Centre and Mbarara University and Referral Hospital Eye 
Centre from December 2016 to March 2018. These are 
the tertiary referral centres for South- Western Uganda. 
The case definition of MK was the presence of a corneal 
epithelial defect (of at least 1 mm diameter) with an 
underlying stromal infiltrate, associated with signs 
of inflammation (conjunctival hyperaemia, anterior 
chamber inflammatory cells, ±hypopyon).9 We excluded 
those not willing to participate or to return for follow- up, 
pregnant women, lactating mothers and those under 18 
years. All the questions in the tools were responded to 
directly by the study participants.
Assessment of cases
At presentation, we documented basic demographic 
information and ophthalmic history. Presenting Loga-
rithm of Minimum Angle of Resolution visual acuity at 
2 m in a dark room was measured using the Peek Acuity 
smartphone application.10 Cases were examined at a slit 
lamp to assess the anterior segment using a structured 
protocol. Corneal scrape specimens were collected from 
the ulcer at a slit lamp or an operating microscope and 
samples were processed in the department of microbi-
ology laboratory at Mbarara University of Science and 
Technology. Following corneal scrapping, immediate 
Calcofluor White staining was done in the side laboratory 
at the eye hospital on a fluorescence microscope (Zeiss 
Primostar ILED) by the attending ophthalmologist to 
rule out fungal Keratitis. Additional microscopy (Gram 
staining and KOH staining) was done in the main Univer-
sity microbiology laboratory and results became available 
within 24 hours. Agar plates and broths (Blood, Choco-
late, Potato Dextrose and Brain Heart) were incubated 
at 35°C–37°C for bacteria for up to 7 days and at 25°C 
for up to 21 days for fungi. Organism identification and 
sensitivity testing were performed using standard micro-
biological techniques. Cases were treated empirically at 
presentation and the treatment was reviewed when the 
microbiology results became available. Patients with 
fungal keratitis were treated with Natamycin 5% eyedrops 
(Zonat Sunways India), those with bacterial keratitis 
were treated with Ofloxacin 0.3% eyedrops (Biomedica 
Remedies- India). They were reviewed on days 2, 7, 21 and 
90 (3 months). At 3 months, the cases were followed- up 
in their homes for a final assessment.
Control recruitment
We recruited healthy community controls during the 
3- month follow- up of cases in their home village. The 
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Table 2 VRQoL and general HRQoL among cases (baseline and 3 months) and controls (215 pairs)
Domain
Cases at baseline Cases at 3 Months Controls at 3 Months
Adjusted mean difference at 
3 months
Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean * (95% CI) P value †
VRQoL
  Overall sight 32.9 (30.6 to 35.2) 86.3 (83.3 to 89.2) 98.6 (97.5 to 99.6) 11.6 (8.8 to 14.5) <0.0001
  Visual symptom 20.7 (18.8 to 22.7) 88.3 (85.5 to 91.1) 99.4 (98.9 to 99.8) 10.5 (7.7 to 13.3) <0.0001
  General 
functioning
42.8 (40.6 to 45.1) 89.0 (86.1 to 91.9) 99.6 (99.3 to 100) 9.9 (7.1 to 12.7) <0.0001
  Psychosocial 65.6 (62.5 to 68.8) 90.7 (88.1 to 93.3) 99.8 (99.4 to 100) 8.5 (6.0 to 11.0) <0.0001
HRQoL
General facet items
  Overall quality 
of life
40.3 (39.0 to 41.6) 86.6 (83.9 to 89.4) 97.2 (96.4 to 97.9) 10.2 (7.6 to 12.8) <0.0001
  Overall Health 31.0 (29.0 to 33.0) 85.6 (82.7 to 88.5) 98.2 (97.3 to 99.1) 12.0 (9.1 to 14.9) <0.0001
Domains
  Physical health 28.4 (26.5 to 30.3) 86.1 (83.1 to 89.2) 98.3 (97.6 to 98.9) 11.5 (8.6 to 14.5) <0.0001
  Psychological 49.2 (47.5 to 50.9) 84.4 (81.9 to 86.9) 94.0 (93.4 to 94.7) 9.1 (6.7 to 11.5) <0.0001
  Social 48.5 (46.5 to 50.5) 88.2 (85.2 to 91.2) 98.5 (97.6 to 99.3) 9.9 (6.9 to 12.9) <0.0001
  Environment 43 (41.7 to 44.3) 84.8 (82.0 to 87.6) 96.3 (95.2 to 97.3) 10.9 (8.2 to 13.6) <0.0001
Only the cases who had controls were included in this analysis (215 pairs).
*Mean difference between cases and controls adjusted for age, sex and wealth status.
†Linear regression random effects model was used to test for significance of the differences among the cases and controls adjusted for age, 
sex and wealth status.
HRQoL, health- related quality of life; VRQoL, vision- related quality of life.
controls were individuals without any current eye 
complaints and with normal vision. The controls were 
individually matched to the cases. They had to be living 
in same village as the case, be of the same gender and 
in the same age group (±5 years). Enrolment followed a 
similar approach to that previously used in study in Ethi-
opia.6 The research team visited the villages (typically 
50–100 households), the local village head was asked to 
write down all individuals they thought would meet the 
matching criteria for a particular case in that village. One 
person was randomly selected from this list using a lottery 
method. They were approached and provided with 
details of the study and invited to participate if eligible. 
If a selected individual refused or was ineligible, another 
person was randomly selected and approached. Both 
cases and controls were asked about their social economic 
status, this was a self- reported question compared with 
their neighbours on a 5- scale level (5—‘very rich’, 
4—‘rich’, 3—‘neither rich nor poor’, 2—‘poor’, 1—‘very 
poor’).6 7 11 In this 5- point scale, participants were asked 
‘Compared with your neighbours, how do you rate your 
household wealth status?’
QoL instruments
To measure QoL we used two instruments: the general 
health WHOQOL- BREF and the vision- related WHO/
PBD- VF20. BREF stands for abbreviated form of the 
original WHOQOL tool. These were both initially inde-
pendently translated by two translators into Runyankole, 
the local language. Any discrepancies were discussed 
with a third party and a merged final agreed version 
produced. Both instruments were administered to cases 
at presentation and at the 3- month follow- up. They were 
administered to the control group only once, during the 
3- month assessment of the matched case.
VRQoL
the WHO/PBD- VF20 tool measures VRQoL. It assesses 
the impact of visual impairment in several domains 
including mental well- being, dependency and social func-
tioning. The WHO/PBD- VF20 consists of 20 questions 
divided into four subscales: ‘General Vision’ subscale 
(one question); ‘Visual Symptoms’ subscale (three ques-
tions); ‘General Functioning’ subscale (12 questions); 
and ‘Psychosocial’ subscale (four questions). It begins 
by asking the patient ‘Overall, how would you rate your 
eyesight using both eyes?’; and uses a 5- point scale answer 
option such as ‘very good’, ‘good’, ‘moderate’, ‘bad’, 
‘very bad’. Each subsequent question also has a 5- point 
response option: one indicates the highest and five the 
lowest score.
HRQoL
the WHOQOL- BREF (WHOQOL Group, 1998) has 
good applicability in low and middle- income countries as 
it was developed simultaneously from concept across 18 
countries in Africa, Asia and Latin America.12 It measures 
four domains of health: Physical Health, Psychological 
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Table 3 Presenting vision, microbiology and 3- month 
outcomes for the cases (n=260)
Variable n/260 (%)
Presenting visual acuity in the affected eye (Snellen) *
  >6/18 86 (33)
  6/18-6/60 36 (14)
  <6/60 137 (53)
Presenting visual acuity in the non- affected eye (Snellen) *
  >6/18 232 (90)
  6/18-6/60 14 (5)
  <6/60 13 (5)
Microbiology †
  Fungal 143 (63)
  Bacterial 18 (8)
  Mixed 13 (6)
  Unknown 52 (23)
Visual acuity in the affected eye (Snellen) at 3 months
  >6/18 138 (53)
  6/18-6/60 37 (14)
  <6/60 85 (33)
Visual acuity in the non- affected eye at 3 months
  >6/18 229 (90)
  6/18-6/60 11 (4)
  <6/60 15 (6)
Outcome at 3 months
  Healed no scar 34 (12)
  Healed Mild scar 83 (30)
  Healed moderate scar 65 (24)
  Healed dense scar 46 (17)
  Eviscerated 24 (9)
  Not healed 20 (7)
  Staphyloma 4 (1)
*There was one missing value (n=259).
†Corneal scrapping was performed on 226/260 participants; 
it was not possible to obtain corneal scrapping samples in 
34 participants either due to uncooperative patient, declining 
consent, deep infiltrates with intact epithelium, such patients were 
treated based on clinical impression. In all, 52 samples returned 
negative, no organism detected on microscopy or culture, these 
were also managed based on clinical impression.
Health, Social Relationships and Environment. It asks 
respondents 26 questions. These include the frequency 
they have experienced issues and/or were able to do 
things (eg, feel safe, able to concentrate, enjoy life) in 
the past 4 weeks and how satisfied they are with certain 
aspects of their lives (eg, sleep, capacity for work).12
Sample size
Based on the effect sizes found in previous work on cata-
ract and trichiasis, a sample size of 215 pairs would have 
80% power to detect a moderate effect of MK on QoL 
with an effect size of 0.27 (effect size=QoL score differ-
ence (3)/SD 11) with a Type 1 error of 5%.5 7
Analysis
Data were managed in Access (Microsoft), and trans-
ferred to Stata V.14 (StataCorp) for analysis. Data were 
analysed using a previously described methodology, 
applied in other QoL studies.6 7 13
VRQoL
All items were grouped, and scores added into their 
respective subscales: ‘General Vision’ subscale (one 
question); ‘Visual Symptoms’ subscale (three questions); 
‘General Functioning’ subscale (12 questions); and 
‘Psychosocial’ subscale (four questions). The subscale 
scores were then converted into a scaled value out of one 
hundred, using the formula: ((individual score—lowest 
possible score)/(highest possible score—lowest possible 
score)) × 100. Therefore, the person with the lowest 
possible VRQoL score would receive a scaled value of ‘0’ 
and the person with the highest possible VRQoL score 
receives a scaled value of ‘100’.
HRQoL
Data were analysed following the WHOQOL- BREF 
protocol.12 Three negatively framed items were reversed 
into a positive frame so higher scores denote higher QoL. 
To generate domain scores, questions were grouped 
into their respective domains and their scores totalled. 
The mean score of all items included in the domain was 
calculated and then multiplied by four. These scores then 
transformed to a 0 to 100 scale with the formula speci-
fied in the manual to allow comparison between domains 
made of unequal number of items.14
Psychometric property evaluation
Construct validity of the VRQoL and HRQoL data was 
assessed through known- group difference and conver-
gence validity using a linear regression model. Cronbach’s 
alpha was used to test for internal consistency and reli-
ability of the VRQoL and HRQoL data.
Cases and controls were compared for baseline char-
acteristics. However, we noticed that not all the pairs had 
been correctly matched for age because the village heads 
had subjectively guessed the ages of the controls. We thus 
adjusted for age throughout the analysis. The VRQoL and 
HRQoL analysis compared the cases to the controls at 3 
months using a linear regression random effects model, 
which was adjusted for age and socioeconomic status, as 
these factors may confound the association between MK 
and QoL. A linear regression analysis was used to deter-
mine vision- related factors associated with QoL among 
the cases at 3 months adjusted for baseline QoL, age, sex, 
education and economic status.
Patient and public involvement
Apart from helping to provide information during the 
piloting and data collection phase, we did not explicitly 
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Table 4 Univariable and multivariable linear regression for factors associated with VRQoL among cases only (n=260) seen at 
3 months
Variable
Overall sight Visual symptom General functioning Psychosocial
Mean (95%CI) Mean (95%CI) Mean (95%CI) Mean (95%CI)
Visual acuity at 3 months
>6/18 89.7 (86.6 to 92.7) 90.9 (87.6 to 94.2) 93.3 (90.5 to 96.1) 93.3 (90.9 to 96.1)
6/18–6/60 78.4 (69.1 to 87.6) 82.7 (73.5 to 91.8) 82.2 (73.3 to 91.1) 83.3 (74.9 to 91.7)
<6/60 77.4 (71.6 to 83.1) 82.9 (78.3 to 87.6) 81.3 (76 to 86.6) 83.8 (78.7 to 88.9)
P value*† <0.0001 0.006 <0.0001 <0.0001
P value‡† 0.001 0.044 0.006 0.003
Eye removal §
No 83.6 (80.7 to 86.6) 86.5 (83.5 to 89.3) 87.5 (84.6 to 90.3) 88.6 (86 to 91.2)
Yes 87.5 (76.3 to 98.7) 93.1 (86.3 to 99.8) 90.8 (81.6 to 100) 90.8 (81.2 to 100)
P value* 0.406 0.168 0.356 0.619
P value‡ 0.030 0.025 0.054 0.111
*P values from univariable linear regression analysis.
†For visual acuity at 3 months (ordinal exposures with three categories), the p values were calculated for trend.
‡P values from multivariable linear regression analysis, adjusted for age, education status, wealth category and baseline QoL.
§Eye removal was a priori.
VRQoL, vision- related quality of life.
involve patients or the public in the designing and imple-
mentation of our work
ReSuLTS
A total of 313 MK cases presented and were enrolled. 
We were able to follow- up 260 cases at 3 months. It was 
not possible to enrol a control for 45/260 cases. There-
fore, the analysis of QoL at 3 months comprises 215 
pairs. The baseline characteristics were comparable 
among the cases and control group: median age was 
47 years (IQR 35–60, total range 18–96 years), and 120 
(56%) were male. (table 1)
Table 2 shows the baseline and 3- month VRQoL 
and HRQoL scores for the cases and the scores for 
the control group. The mean baseline VRQoL scores 
among the cases were all low (<50) except the psycho-
social domain which had a score of 65 points. The most 
affected domain was visual symptoms, with a mean 
score of 20.7 (95% CI 18.8 to 22.7). The mean baseline 
HRQoL scores among the cases were all low (<50). At 
3 months, all the case VRQoL and HRQoL scores had 
increased and were relatively high (between 80 and 91). 
Despite this increase, there was still very strong evidence 
(p<0.0001 in all domains) that QoL scores among MK 
cases at 3 months were lower than the controls, after 
adjusting for age, and economic status.
Table 3 shows the presenting vision, microbiology 
and 3- month outcomes among the 260 cases. Majority 
(137/260) presented with vision worse than 6/60 in 
the affected eye. Microbiology results were available for 
226/260 participants out of which the majority (63%) 
showed fungal keratitis. At 3 months, 138/260 had 
vision of better than 6/18 in the affected eye. Vision had 
improved in 137 individuals, remained the same in 56 
and worsened in 66 participants (sign rank p<0.0001).
To investigate whether the difference in QoL between 
the cases and controls was due to factors in addition to 
impaired vision in the MK group, a separate subgroup 
analysis was performed comparing only MK cases with 
normal vision in the affected eye (better than 6/18) to 
their paired controls (online supplementary table 1). It 
was observed that the differences in QoL was similar to 
that obtained when using all the cases.
Tables 4 and 5 show factors associated with a good 
VRQoL and HRQoL among the cases at 3 months. 
This analysis was among all the 260 MK cases who were 
followed up at 3 months. Analysis was restricted to vari-
ables related to the disease such as vision at 3 months 
and whether the person had lost their eye. They were 
adjusted for sex, age, education, baseline QoL and 
socioeconomic status. Vision and eye loss were the both 
found to be associated with VRQoL and HRQoL.
Validity of the data was found to be good. Satisfying the 
known- groups difference criteria, the cases had signifi-
cantly lower VRQoL and HRQoL scores in all domains 
(p<0.0001) than the controls (table 2). The VRQoL 
data were reliable after being assessed for internal 
consistency with a Cronbach’s alpha: coefficients of 
>0.80 (visual symptom 0.90, general functioning 0.98, 
psychosocial 0.87). The overall HRQoL data had a 
Cronbach’s alpha of 0.98 (physical health 0.96, psycho-
logical 0.89, social 0.91 and environment 0.95).
diSCuSSion
This study investigated the impact of MK on QoL in 
Uganda. Overall, both the VRQoL and HRQoL among 
MK patients at baseline was substantially reduced. The 
lowest scores were in the visual symptom (most had 
reduced vision) and physical health (most were in 
pain) categories. The least affected domain at baseline 
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was psychological, which assesses ability to attend func-
tions, feeling ashamed, feeling like a burden to others 
and fear of losing the other eye. In the only other 
published QoL study in people with MK, the MUTT1 
study from India, QoL at the time of presentation was 
not reported.8
The QoL scores among the MK cases had improved 
greatly by 3 months. However, compared with the control 
group, there was strong evidence that MK results in a 
persistent reduction in QoL, with a mean difference in 
QoL scores of around 10 points. This effect remained 
evident even when MK cases with impaired vision were 
excluded from the analysis.
In looking at factors associated with QoL among 
MK cases at 3 months, after adjusting for other factors 
that may affect QoL, such as age, sex, education and 
economic status, visual acuity was an important determi-
nant for both VRQoL and HRQoL. There was evidence 
that a history of eye loss was also associated with both 
VRQoL and HRQoL at 3 months. It was surprising to 
note that the people who had undergone evisceration 
had generally better QoL scores compared with those 
who did not. At the time of eye removal, most of the 
eyes were too damaged and painful that the people 
were ‘demanding’ for eye removal. They received 
socket prostheses (artificial eyes) after their eye removal 
procedures, this could have led to a marked reduction 
in pain and other unpleasant symptoms after eviscera-
tion, which led to a less impaired QoL compared with 
others who were not eviscerated where there would 
have been some with ongoing pain and other symptoms 
like dense corneal scars.
Validity and reliability of QoL data
These tools have been used in a number of other vision- 
related studies to show a difference in QoL and have been 
reported to be valid and reliable in studies conducted 
in similar settings.5–7 Although the WHO/PBD- VF20 
tool was designed to assess binocular vision, it has been 
demonstrated to be effective in detecting differences 
in monocular visual impairment in the MUTT1 trial 
where patients randomised to natamycin had a better 
3- month visual- related QoL outcome compared with 
patients randomised to variconazole.8 In this study, both 
the VRQoL and HRQoL data measured what they were 
intended to measure (construct validity) by demon-
strating evidence of differences in the scores between 
groups known to be different; MK cases and healthy 
controls had lower and higher scores, respectively. The 
VRQoL data also showed that subscales correlate well 
with measures of impact of MK on QoL such as visual 
acuity where worsening in these measures is associated 
with lower VRQoL subscale scores (construct validity). 
There was evidence of higher homogeneity among the 
items in each VRQoL and HRQoL subscale (internal 
consistency) than the generally accepted criteria of 
>0.70. Cronbach’s alpha scores ranged from 0.80 to 
0.99 across all sub scales.
Strengths/limitations
This was the first study to look at impact of MK on 
QoL and compare these with unaffected controls. The 
control selection was good and matched for age, sex and 
village. We used validated tools which have been previ-
ously applied in similar settings and the sample size was 
adequate to test for differences in QoL. This study did 
not collect baseline QoL information from the control 
group because it was not logistically possible. Informa-
tion on other ocular comorbidities such as presence of 
a cataract and posterior segment disease at 3 months 
was not collected as these examination were conducted 
at patients’ homes and it was not practical to perform a 
full eye examination in such settings.
ConCLuSion
This study showed that MK severely affects QoL in the 
acute phase. With treatment, QoL improves, with the 
highest QoL in cases who had little or no visual impair-
ment at 3 months. Despite this impressive improvement, 
the QoL at 3 months of someone previously affected by 
MK (even when they have normal vision) remains lower 
than controls.
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